ICAD Inc
NASDAQ:ICAD

Watchlist Manager
ICAD Inc Logo
ICAD Inc
NASDAQ:ICAD
Watchlist
Price: 3.87 USD 3.75% Market Closed
Market Cap: $106.3m

ICAD Inc
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ICAD Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
ICAD Inc
NASDAQ:ICAD
Gross Profit
$16.7m
CAGR 3-Years
-10%
CAGR 5-Years
-7%
CAGR 10-Years
-7%
Veeva Systems Inc
NYSE:VEEV
Gross Profit
$2.4B
CAGR 3-Years
16%
CAGR 5-Years
18%
CAGR 10-Years
25%
Inspire Medical Systems Inc
NYSE:INSP
Gross Profit
$778.8m
CAGR 3-Years
32%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Gross Profit
$514.5m
CAGR 3-Years
19%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Gross Profit
$508m
CAGR 3-Years
-5%
CAGR 5-Years
4%
CAGR 10-Years
7%
W
Waystar Holding Corp
NASDAQ:WAY
Gross Profit
$751.1m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ICAD Inc
Glance View

Market Cap
106.3m USD
Industry
Health Care

iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 136 full-time employees. The firm operates through two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). In the Detection segment, the Company’s solutions include advanced image analysis and workflow solutions enables healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, and a comprehensive range of artificial intelligence and computer aided detection (CAD) systems and workflow solutions for two-dimension(2D) and third dimension (3D) mammography, magnetic resonance imaging (MRI) and computed tomography (CT). In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

ICAD Intrinsic Value
1.04 USD
Overvaluation 73%
Intrinsic Value
Price $3.87

See Also

What is ICAD Inc's Gross Profit?
Gross Profit
16.7m USD

Based on the financial report for Mar 31, 2025, ICAD Inc's Gross Profit amounts to 16.7m USD.

What is ICAD Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
-7%

Over the last year, the Gross Profit growth was 13%. The average annual Gross Profit growth rates for ICAD Inc have been -10% over the past three years , -7% over the past five years , and -7% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett